Xiamen Amoytop Biotech Co Ltd (688278) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xiamen Amoytop Biotech Co Ltd (688278) has a cash flow conversion efficiency ratio of 0.197x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥332.29 Million ≈ $48.63 Million USD) by net assets (CN¥1.69 Billion ≈ $247.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Xiamen Amoytop Biotech Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Xiamen Amoytop Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Xiamen Amoytop Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xiamen Amoytop Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xiamen Amoytop Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fermi Inc.
NASDAQ:FRMI
|
0.073x |
|
Multistrada Arah Sarana Tbk
JK:MASA
|
0.131x |
|
Guangdong Dongfang Precision Science & Technology Co Ltd
SHE:002611
|
0.060x |
|
Academy Sports Outdoors Inc
NASDAQ:ASO
|
0.069x |
|
Camurus AB
ST:CAMX
|
0.060x |
|
Hubei TKD Crystal Electn
SHG:603738
|
0.015x |
|
ATHENS INTERNATIONAL AIRPORT S.
AT:AIA
|
N/A |
|
Loomis AB ser. B
ST:LOOMIS
|
0.098x |
Annual Cash Flow Conversion Efficiency for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 688278 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.55 Billion ≈ $373.63 Million |
CN¥430.63 Million ≈ $63.02 Million |
0.169x | -38.20% |
| 2023-12-31 | CN¥1.88 Billion ≈ $274.58 Million |
CN¥512.10 Million ≈ $74.94 Million |
0.273x | +5.78% |
| 2022-12-31 | CN¥1.41 Billion ≈ $205.98 Million |
CN¥363.16 Million ≈ $53.14 Million |
0.258x | +27.61% |
| 2021-12-31 | CN¥1.16 Billion ≈ $169.93 Million |
CN¥234.78 Million ≈ $34.36 Million |
0.202x | +118.40% |
| 2020-12-31 | CN¥1.00 Billion ≈ $146.39 Million |
CN¥92.61 Million ≈ $13.55 Million |
0.093x | -57.69% |
| 2019-12-31 | CN¥563.55 Million ≈ $82.47 Million |
CN¥123.30 Million ≈ $18.04 Million |
0.219x | +22.53% |
| 2018-12-31 | CN¥499.26 Million ≈ $73.06 Million |
CN¥89.15 Million ≈ $13.04 Million |
0.179x | +856.57% |
| 2017-12-31 | CN¥483.26 Million ≈ $70.72 Million |
CN¥-11.41 Million ≈ $-1.67 Million |
-0.024x | -126.59% |
| 2016-12-31 | CN¥478.09 Million ≈ $69.96 Million |
CN¥42.43 Million ≈ $6.21 Million |
0.089x | -- |
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.